Oncotarget is a free access journal that publishes research article online on a weekly basis. This journal is committed to disseminating scientific information promptly. Oncotarget works in collaboration with other partners, including Wellcome Trust Publishers and PubMed. In the last couples of years, this journal has become famous in the scientific world due to its multiple peer-review, constructive, insightful, and punctual research works and more information click here.
Oncotarget serves to increase the impact of research. It publishes papers in the disciplines such as:
- Autophagy and cell death
- Immunology and Microbiology
Oncotarget is flexible and can post each article based on customer demand. This journal serves to minimize the gap between various specialties, allowing findings to be disseminated quickly to maximize the impact of research. Additionally, Oncotarget serves to merge the different fields of medicine, and foster the adoption new clinical sciences to fight illnesses. This journal is involved in sponsoring various research and scientific meetings. Oncotarget is the principal sponsor of the Gordon Research Conference, a meeting recently held on July 2017 at the University of New England. Mr. Howard Crawford and Mr. Rama Khokha chaired this conference and Oncotarget on Facebook.
The leadership of the journal
Dr. Mikhail Blagosklonny and Andrei V. Gudkov founded Oncotarget. These two scientists work at the Roswell Park Cancer Institute, Buffalo, New York. Dr. Mikhail Blagosklonny is an expert in hematology, oncology, and clinical trials. He has authored over 279 research items, which have since acquired over 10,487 reads and 24,213 citations. Dr. Mikhail Blagosklonny’s expertise ranges from cancer metastasis, chemoprevention, cell invasion, and senescence. This expert is a senior editor of numerous journals, including Oncotarget, Cancer Biology & Therapy, Cancer Research, PLoS ONE, the International Journal of Cancer, and the American Journal of Pathology.
Under Dr. Mikhail Blagosklonny’s management, this company has won numerous awards, including the Breakthrough Prize, one of the most prestigious awards in science. Oncotarget also works with other renowned scientists, including Stephen J. Elledge, Bert Vogelstein, Michael N. Hall, and Alexander Varshavsky. Oncotarget is considering increasing its publication frequency through publishing more than two papers per week. This idea came about due to the growing demand for knowledge. Oncotarget is expected to liaise with PubMed to actualize this idea and learn more about Oncotarget.